Study of Satisfaction of Patients and Care Providers for an Alternate Follow-up With In-hospital Consults and Tele-consult for Patients With Cystic Fibrosis

NCT ID: NCT05249322

Last Updated: 2023-09-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-31

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The pandemic forced us to develop home follow-up for patients with chronical diseases . In the same time, the new era of treatment for cystic fibrosis considerably improves the health of patients with this pathology.

This study aims to assess the satisfaction of patients and care providers for an alternated follow-up between tele-consults and in-hospital consults during one year for patients with cystic fibrosis treated by Kaftrio® since at least one year and stable.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Follow-up alternating between face-to-face consultation and teleconsultation every three months

Patients of this arm will be followed alternating between face-to-face consultation and teleconsultation respecting the recommended frequency (every three months) during 12 months (M+3:teleconsultation - M+6:in-hospital consultation - M+9:teleconsultation - M+12 : in-hospital consultation)

Group Type EXPERIMENTAL

Follow-up alternating between face-to-face consultation and teleconsultation every three months.

Intervention Type OTHER

The intervention will be an alternate follow-up every three months with:

* A tele-consult: with paramedical consult (with assistance for home-spirometry) and medical consult for about 1h30 in total, make with a HCL platform for telemedicine.
* An usual in-hospital consult of about 1h30 with paramedical and medical consult.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Follow-up alternating between face-to-face consultation and teleconsultation every three months.

The intervention will be an alternate follow-up every three months with:

* A tele-consult: with paramedical consult (with assistance for home-spirometry) and medical consult for about 1h30 in total, make with a HCL platform for telemedicine.
* An usual in-hospital consult of about 1h30 with paramedical and medical consult.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with cystic fibrosis
* Patients treated with Kaftrio® since one year
* autonomous patients
* patients without cognitive disorders
* Patients voluntary for this follow up
* patients with two tele-communication tools
* patients with FEV1\>50%
* patients with less of 2 antibiotics cure per year

Exclusion Criteria

* all transplanted patients
* Pregnant patients
* Particular follow up needed in-hospital consult
* Persons deprived of their liberty by a judicial or administrative decision
* Persons subject to psychiatric care
* Persons admitted to a health or social establishment for purposes other than research
* Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas VIDAL

Role: PRINCIPAL_INVESTIGATOR

adult cystic fibrosis centre Lyon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Lyon Sud

Pierre-Bénite, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Thomas VIDAL

Role: CONTACT

478865671 ext. +33

Isabelle Durieu, Pr

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Thomas VIDAL

Role: primary

478865671 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A00134-39

Identifier Type: OTHER

Identifier Source: secondary_id

69HCL21_1354

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

COVID-19 Antibody Responses in Cystic Fibrosis
NCT05614336 ACTIVE_NOT_RECRUITING NA